Respiratory syncytial virus, or RSV, might not be a name you hear every day, but it’s a virus that can cause serious trouble for older adults. While RSV often gets discussed as a childhood illness, it’s also a major concern for seniors, particularly those with other health conditions. .
The research focused on adults aged 60 and older in the United States during the first RSV season after the vaccine became available. Many participants had conditions like heart disease, diabetes, or weakened immune systems—exactly the people at highest risk of landing in the hospital with severe RSV.
So, what did the researchers find? The RSV vaccine worked well. The study showed that the vaccine reduced the risk of severe RSV-related disease requiring hospitalization or emergency department visits by about 90%. That’s an impressive level of protection, especially considering that many participants were over 75 and had complex medical histories.
The study also emphasized that RSV isn’t just a minor cold for older adults. It can lead to pneumonia, worsening chronic conditions, and long hospital stays. For years, RSV has been an overlooked threat, but with the vaccine now available, we finally have a tool to keep high-risk adults safer during RSV season.
These findings are great news, but they also come with a reminder: vaccines aren’t just about individual protection—they also help reduce the burden on hospitals and clinics during peak respiratory illness seasons. With other viruses like influenza and COVID-19 circulating, anything we can do to prevent severe illness makes a difference.
For older adults and their loved ones, this research highlights how effective the RSV vaccine can be in preventing trips to the emergency room and serious complications. As RSV continues to make headlines during the colder months, getting vaccinated can be a simple but powerful step toward staying healthy.
If you’re over 60 or have loved ones in this age group, now is a good time to talk to your healthcare provider about RSV vaccination.
Reference: Tartof SY, Aliabadi N, Goodwin G, et al. Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease. JAMA Netw Open. 2024;7(12):e2450832. doi:10.1001/jamanetworkopen.2024.50832.
----------
Thank you for reading! If you like what we researched for you and presented in this blog post, and would like to read more blog posts like this, please consider signing up for email updates by